[{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Longeveron \/ EF Hutton","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ EF Hutton"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Lomecel-B","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"VEGF receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"VEGF receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Longeveron \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Longeveron

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The Company intends to use the net proceeds for its ongoing clinical and regulatory development of Lomecel-B (laromestrocel) for the treatment of several disease states and indications.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          August 11, 2025

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $17.5 million

                          Deal Type : Public Offering

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The Company intends to use the net proceeds for its ongoing clinical and regulatory development of Lomecel-B (laromestrocel) for the treatment of several disease states and indications.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          August 08, 2025

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $17.5 million

                          Deal Type : Public Offering

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lomecel-B is a preparation of multipotent stem & progenitor cells isolated from bone marrow of young healthy adults. It is being evaluated for the treatment of mild alzheimer's disease.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The company intends to use the net proceeds from the offering for its ongoing clinical and regulatory development of Lomecel-B to treat several disease states and indications, including HLHS and AD.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          July 18, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $9.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lomecel-B is a preparation of multipotent stem & progenitor cells isolated from bone marrow of young healthy adults. It is being evaluated for the treatment of mild alzheimer's disease.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 17, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lomecel-B is a preparation of multipotent stem & progenitor cells isolated from bone marrow of young healthy adults. It is being evaluated for the treatment of mild alzheimer's disease.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 10, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The net proceeds from the transaction for its ongoing clinical development of Lomecel-B (Allogeneic Medicinal Signaling Cell Therapy) for the treatment of several disease including HLHS.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          June 18, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $4.4 million

                          Deal Type : Public Offering

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The net proceeds from the transaction for its ongoing clinical development of Lomecel-B (Allogeneic Medicinal Signaling Cell Therapy) for the treatment of several disease including HLHS.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          June 17, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $4.4 million

                          Deal Type : Public Offering

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lomecel-B (allogeneic bone marrow-derived medicinal signaling cells), isolated from bone marrow of young healthy adults, which is being evaluated for the treatment of Hypoplastic Left Heart Syndrome.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          June 11, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The Company plans to use net proceeds for ongoing clinical development of Lomecel-B, an allogeneic signaling cell therapy, for treating HLHS, Alzheimer’s disease, and other indications.

                          Product Name : Lomecel-B

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          April 18, 2024

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $11.4 million

                          Deal Type : Public Offering

                          blank